Streetbeat News

ECOR

electroCore, Inc.

https://www.electrocore.com

Industry

Medical - Devices

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Open

15.52

Mkt cap

101M

Volume

294K

High

15.97

P/E Ratio

-8.75

52-wk high

19.49

Low

13.90

Div yield

N/A

52-wk low

5.32

Ecora Resources has announced a $50 million deal to acquire an interest in a copper revenue stream from Moxico Resources' Mimbula copper mine in Zambia. This move aligns with Ecora's strategy to focus on royalties and streams, promising immediate earnings and cash flow growth.

Portfolio Pulse from

March 01, 2025 | 10:15 am

electroCore, Inc. has entered into an agreement with Spark Biomedical to distribute the FDA-cleared Sparrow Ascent device for opioid withdrawal in certain VA facilities.

Portfolio Pulse from

February 27, 2025 | 1:15 pm

Ecora Resources has acquired a copper stream from Moxico Resources' Mimbula copper mine in Zambia for $50 million, covering the mine's 11-year Life of Mine with potential for extension.

Portfolio Pulse from

February 27, 2025 | 8:00 am

electroCore (ECOR) has been identified as a strong choice for trend investors due to its recent price strength, suggesting potential for profit as the stock is currently on the move.

Portfolio Pulse from

February 12, 2025 | 3:00 pm

electroCore, Inc. (Nasdaq: ECOR) will participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11-12, 2025, in Snowbird, Utah.

Portfolio Pulse from

February 04, 2025 | 1:15 pm

Ecora Resources PLC reported a portfolio income of US$63 million for 2024, slightly above market estimates. The company has started receiving a contingent consideration from Narrabri, with US$3 million already received in January.

Portfolio Pulse from

January 29, 2025 | 3:30 pm

Ecora Resources reported a 29% increase in income for the fourth quarter, driven by record production volumes at Voisey's Bay and Mantos Blancos. This highlights the company's strong performance in copper and cobalt production.

Portfolio Pulse from

January 29, 2025 | 7:45 am

electroCore (ECOR) is highlighted as a stock with strong recent price momentum, making it a potential choice for investors looking for stocks with an uptrend.

Portfolio Pulse from

January 27, 2025 | 3:00 pm

electroCore, Inc. (ECOR) is showing promising growth with a 45% year-over-year revenue increase and a 38% reduction in losses. Despite missing revenue expectations, the company is focusing on profitability with high gross margins and decreasing operating expenses as a percentage of revenue. The FDA-cleared gammaCore device for headaches and expanding product lines indicate strong potential and barriers to entry.

Portfolio Pulse from

January 14, 2025 | 3:30 pm

electroCore is expanding its market reach with its FDA-approved gammaCore device, targeting the VA system and other healthcare channels. The company is diversifying with new products for military and wellness markets and has acquired NeuroMetrix's Quell system, enhancing revenue and cost synergies.

Portfolio Pulse from

December 30, 2024 | 7:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.